Literature DB >> 27189265

Attention-deficit/hyperactivity disorder.

Stephen V Faraone1,2, Philip Asherson3, Tobias Banaschewski4, Joseph Biederman5, Jan K Buitelaar6, Josep Antoni Ramos-Quiroga7,8,9, Luis Augusto Rohde10,11, Edmund J S Sonuga-Barke12,13, Rosemary Tannock14,15, Barbara Franke16.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a persistent neurodevelopmental disorder that affects 5% of children and adolescents and 2.5% of adults worldwide. Throughout an individual's lifetime, ADHD can increase the risk of other psychiatric disorders, educational and occupational failure, accidents, criminality, social disability and addictions. No single risk factor is necessary or sufficient to cause ADHD. In most cases ADHD arises from several genetic and environmental risk factors that each have a small individual effect and act together to increase susceptibility. The multifactorial causation of ADHD is consistent with the heterogeneity of the disorder, which is shown by its extensive psychiatric co-morbidity, its multiple domains of neurocognitive impairment and the wide range of structural and functional brain anomalies associated with it. The diagnosis of ADHD is reliable and valid when evaluated with standard criteria for psychiatric disorders. Rating scales and clinical interviews facilitate diagnosis and aid screening. The expression of symptoms varies as a function of patient developmental stage and social and academic contexts. Although there are no curative treatments for ADHD, evidenced-based treatments can markedly reduce its symptoms and associated impairments. For example, medications are efficacious and normally well tolerated, and various non-pharmacological approaches are also valuable. Ongoing clinical and neurobiological research holds the promise of advancing diagnostic and therapeutic approaches to ADHD. For an illustrated summary of this Primer, visit: http://go.nature.com/J6jiwl.

Entities:  

Mesh:

Year:  2015        PMID: 27189265     DOI: 10.1038/nrdp.2015.20

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  295 in total

1.  [The German research network for mental disorders].

Authors:  M Bauer; T Banaschewski; A Heinz; I Kamp-Becker; A Meyer-Lindenberg; F Padberg; M A Rapp; R Rupprecht; F Schneider; T G Schulze; H-U Wittchen
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

2.  Methylphenidate increases willingness to perform effort in adults with ADHD.

Authors:  Merideth A Addicott; Julia C Schechter; Jeffrey J Sapyta; James P Selig; Scott H Kollins; Margaret D Weiss
Journal:  Pharmacol Biochem Behav       Date:  2019-06-18       Impact factor: 3.533

3.  ERK/MAPK Signaling Is Required for Pathway-Specific Striatal Motor Functions.

Authors:  Scott R Hutton; James M Otis; Erin M Kim; Yashna Lamsal; Garret D Stuber; William D Snider
Journal:  J Neurosci       Date:  2017-07-21       Impact factor: 6.167

4.  Familial Liability to Epilepsy and Attention-Deficit/Hyperactivity Disorder: A Nationwide Cohort Study.

Authors:  Isabell Brikell; Laura Ghirardi; Brian M D'Onofrio; David W Dunn; Catarina Almqvist; Søren Dalsgaard; Ralf Kuja-Halkola; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2017-08-12       Impact factor: 13.382

5.  What motivates individuals with ADHD? A qualitative analysis from the adolescent's point of view.

Authors:  Sarah Morsink; Edmund Sonuga-Barke; Gabry Mies; Nathalie Glorie; Jurgen Lemiere; Saskia Van der Oord; Marina Danckaerts
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-02-23       Impact factor: 4.785

6.  Increased Oxidative Parameters and Decreased Cytokine Levels in an Animal Model of Attention-Deficit/Hyperactivity Disorder.

Authors:  Douglas Teixeira Leffa; Bruna Bellaver; Carla de Oliveira; Isabel Cristina de Macedo; Joice Soares de Freitas; Eugenio Horacio Grevet; Wolnei Caumo; Luis Augusto Rohde; André Quincozes-Santos; Iraci L S Torres
Journal:  Neurochem Res       Date:  2017-06-29       Impact factor: 3.996

7.  An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility.

Authors:  Ariel F Martinez; Yu Abe; Sungkook Hong; Kevin Molyneux; David Yarnell; Heiko Löhr; Wolfgang Driever; Maria T Acosta; Mauricio Arcos-Burgos; Maximilian Muenke
Journal:  Biol Psychiatry       Date:  2016-07-14       Impact factor: 13.382

8.  Parenting as a Mechanism of Change in Psychosocial Treatment for Youth with ADHD, Predominantly Inattentive Presentation.

Authors:  Lauren M Haack; Miguel Villodas; Keith McBurnett; Stephen Hinshaw; Linda J Pfiffner
Journal:  J Abnorm Child Psychol       Date:  2017-07

9.  Young Adult Outcomes for Children With 22q11 Deletion Syndrome and Comorbid ADHD.

Authors:  Lea E Taylor; Wendy R Kates; Wanda Fremont; Kevin M Antshel
Journal:  J Pediatr Psychol       Date:  2018-07-01

10.  Validity of proposed DSM-5 ADHD impulsivity symptoms in children.

Authors:  Gül Ünsel Bolat; Eyüp Sabri Ercan; Giovanni Abrahão Salum; Öznur Bilaç; Rafael Massuti; Taciser Uysal Özaslan; Hilmi Bolat; Luis Augusto Rohde
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-03-15       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.